The three-year efficacy of Iguratimod in clinical daily practice in patients with rheumatoid arthritis

Primary tabs

SCIENCE
The three-year efficacy of Iguratimod in clinical daily practice in patients with rheumatoid arthritis
Key Take-Away: 

Rheumatoid arthritis, a chronic inflammatory form of arthritis targets synovial tissue and leads to inflammation of joints following bone, cartilage and tendon damage. Various medications are present to manage the disease, but due to adverse effects of some medicines, researchers identified Iguratimod, a newly developed DMARD efficacy among the RA patients.

Introduction
The study aimed to evaluate the middle-term result of Iguratimod (IGU) for rheumatoid arthritis (RA).

 

Methods
A total of 69 patients taking IGU-containing therapies were selected and categorized into three groups; IGU group, a biologics plus IGU group and a Methotrexate (MTX) plus IGU group. The clinical course and baseline features were estimated over three years. Statistical analysis was done to evaluate the link between the success of low disease activity (LDA) and predictive factors.

 

Results
IGU therapy shows a 40.6% survival rate at three years. As compared to baseline, other two groups exhibited a significant decrease in the disease activity. 55.1% of patients had LDA or in remission at three years. The factors correlated with the achievement of LDA or remission were the use of prednisolone (PSL), DAS28-CRP, and patients gender.

 

Conclusions
The IGU presents considerable efficacy in combination with MTX as well as individually.

Source:

Modern Rheumatology

Link to the source:

https://www.tandfonline.com/doi/abs/10.1080/14397595.2018.1510879

Original title of article:

The three-year efficacy of Iguratimod in clinical daily practice in patients with rheumatoid arthritis

Authors:

Takahito Suto et al.

Therapeutic, Iguratimod, Rheumatoid Arthritis, Joints, DMARD, Efficacy
Log in or register to post comments